BridgeBio Pharma's Heart Disease Drug Succeeds in Late-Stage Study

BridgeBio Pharma's experimental drug, acoramidis, has shown statistically significant improvement in reducing hospitalizations in a late-stage study for a rare heart disease that can lead to heart failure. The company plans to submit marketing applications to the US FDA by the end of 2023 and pursue regulatory filings in additional markets in 2024. Shares of BridgeBio Pharma surged 64% following the positive results.